

Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims

1. (Currently Amended) A method for eliciting an immune response against EBV in a subject, said method comprising:
 - (a) ~~identifying~~ providing a subject ~~identified as being~~ in need of vaccination against EBV, ~~wherein said subject expresses~~ and as expressing one or more HLA class II molecules selected from the group consisting of HLA-DR1, HLA-DR7, HLA-DR16, HLA-DR52, HLA-DQ2, and HLA-DQ7; and
 - (b) administering to said subject an EBV peptide epitope having the amino acid sequence set forth in SEQ ID NO:1.
2. (Original) The method of claim 1, further comprising administering to said subject one or more immune-enhancing agents.
3. (Original) The method of claim 2, wherein said one or more immune-enhancing agents comprise an adjuvant.
4. (Original) The method of claim 3, wherein said adjuvant is Montanide ISA-51.
5. (Original) The method of claim 2, wherein said one or more immune-enhancing agents comprise a cytokine.
6. (Original) The method of claim 5, wherein said cytokine is granulocyte macrophage-colony stimulating factor.
7. (Original) The method of claim 2, wherein said one or more immune-enhancing agents comprise a co-stimulatory molecule.
8. (Original) The method of claim 1, wherein said subject has, is suspected of having, or is at risk for a post-transplant lymphoproliferative disorder.

9. (Currently Amended) A method for eliciting an immune response in a subject, said method comprising administering to said subject (a) an EBV peptide epitope having the amino acid sequence set forth in SEQ ID NO:1, and (b) one or more immune-enhancing agents, wherein said subject expresses one or more HLA class II molecules selected from the group consisting of HLA-DR1, HLA-DR7, HLA-DR16, HLA-DR52, HLA-DQ2, and HLA-D7.
10. (Cancelled)
11. (Original) The method of claim 9, wherein said one or more immune-enhancing agents comprise an adjuvant.
12. (Original) The method of claim 11, wherein said adjuvant is Montanide ISA-51.
13. (Original) The method of claim 9, wherein said one or more immune-enhancing agents comprise a cytokine.
14. (Original) The method of claim 13, wherein said cytokine is granulocyte macrophage-colony stimulating factor.
15. (Original) The method of claim 9, wherein said one or more immune-enhancing agents comprise a co-stimulatory molecule.
- 16-52. (Canceled)